FDA panel reviews 1st new Alzheimer’s drug in 2 decades
A panel of outside experts meets Friday to advise the Food and Drug Administration on aducanumab, a drug from Cambridge, Massachusetts-based Biogen Inc. and Japan’s Eisai Co. FDA doesn’t always follow the panel’s advice but usually does and has until March to decide.
via FOX BUSINESS NEWS Markets
https://ift.tt/38f7cTK
Post a Comment